Expertise in
15
conditions

Roch Houot

CHU Rennes
Rennes, FR 
Expertise in
15
conditions
CHU Rennes
Rennes, FR 
OverviewLocationsClinical Research

Overview

Roch Houot practices in Rennes, France. Mr. Houot is highly rated in 15 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Hodgkin Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 223 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

CHU Rennes
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 01, 2025
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Obinutuzumab, RO7082859
Study Phase: Phase 2
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1/Phase 2
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Other
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Lenalidomide and GA101
Study Phase: Phase 1/Phase 2
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Enrollment Status: Completed
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
A Prospective Phase II Study of Bendamustine in Patients Aged Over 60 Years With Classical Hodgkin Lymphoma Treated by Prednisone, Vinblastine and Doxorubicin
A Prospective Phase II Study of Bendamustine in Patients Aged Over 60 Years With Classical Hodgkin Lymphoma Treated by Prednisone, Vinblastine and Doxorubicin
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

223 Total Publications

Large B-cell lymphoma: The LYSA pragmatic guidelines.
Large B-cell lymphoma: The LYSA pragmatic guidelines.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Houot's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile